ZM336372|Purchase|Buy|Price from|DC Chem

Cas No.:	208260-29-1
Chemical Name:	Benzamide, 3-(dimethylamino)-N-[3-[(4-hydroxybenzoyl)amino]-4-methylphenyl]-
Synonyms:	ZM 336372, ZM-336372
SMILES:	CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC=C2)N(C)C)NC(=O)C3=CC=C(C=C3)O
Formula:	C₂₃H₂₃N₃O₃
M.Wt:	389.45
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

ZM 336372 is a potent inhibitor of the protein kinase c-Raf. The IC50 value is 0.07 μM in the standard assay, which contains 0.1 mM ATP.

In Vitro:

ZM 336372 is a potent inhibitor of human c-Raf. The IC50 value is 0.07 μM in the standard assay, which contains 0.1 mM ATP. The IC50, decreases to 0.01μM at 0.025 mM ATP and increases to 0.9 μM at 2.5 mM ATP indicating that ZM 336372 is a competitive inhibitor with respect to ATP. ZM 336372 inhibits c-Raf tenfold more potently than B-Raf[1]. Cell proliferation analysis of ZM336372. 3,4-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide growth assay of H727 and BON treated as control, DMSO, and 100 μM ZM336372 to days 16 and 10, respectively. Both H727 and BON cell proliferation is inhibited in the presence of drug compared with controls. H727 cells treated with ZM336372 are growth suppressed, whereas control treatments have significantly more growth by day 6, continuing up to 16 days. A similar response is also seen in BON cells as growth suppression occurred as early as day 4 and was maintained out to day 10[2].

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101
2018-0101

Cat. No.	Product name	Field of application
DC47985	GNE-9815	GNE-9815 is among the most highly kinase-selective RAF inhibitors targeting KRAS mutant cancers via combination treatment.
DC7719	ZM336372	ZM 336372 is a potent and selective c-Raf inhibitor with IC50 of 70 nM, 10-fold selectivity over B-RAF, no inhibition to PKA/B/C, AMPK, p70S6, etc.
DC7307	TAK-632	TAK-632 is a selective pan-RAF kinase inhibitor with IC50 values of 2.4/1.4 nM for BRAF V600E/c-RAF; > 60 fold selectivity over VEGFR.
DC8791	Sorafenib free base (BAY-43-9006)	Sorafenib(BAY 43-9006) is a potent inhibitor of Raf-1 with IC50 values of 6 nM, 22 nM and 90 nM for Raf-1, B-Raf, and VEGFR2 respectively, BAY 43-9006 suppresses both wild-type and V599E mutant BRAF activity in vitro.
DC2098	Sorafenib (BAY-43-9006)	Sorafenib Tosylate (Bay 43-9006, Nexavar) is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively.
DC7279	SB-590885	SB590885 is a potent B-Raf inhibitor with Ki of 0.16 nM, 11-fold greater selectivity for B-Raf over c-Raf, no inhibition to other human kinases.
DC9987	RAF709	RAF709 is a novel Raf kinase inhibitor extracted from patent WO2014151616A1, compound example 131, has an IC50 of 0.5 and 1.8 nM for c-Raf and b-Raf, respectively.
DC5049	RAF265 (CHIR-265)	RAF265 (CHIR-265) is a highly selective B-Raf and VEGFR2 inhibitor with IC50 of 3-60 nM and EC50 of 30 nM, including B-Raf, C-Raf and mutant B-Raf.
DC9814	PLX7904(PB04)	PLX7904(PB04) is a potent and selective paradox-breaker RAF inhibitor.
DC6301	PLX-4720	PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.